Published evidence under the name Adamax
- Reported quantity
- None identified in indexed literature
- Frequency
- —
- Study duration
- —
Quantities quoted commercially are extrapolated from Semax, not measured for this molecule.
Protocols · Immune
Adamax: literature-reported ranges
Adamax is sold as a modified, more stable Semax analogue. There is effectively no indexed peer-reviewed literature under this name, and that absence is the single most important thing to know about it.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
- Class
- Cyclic Semax analogue (cyclo-prolylglycine related)
- Reported half-life
- Not characterised in published work
- Routes used in the literature
- Intranasal, by analogy with Semax
- Also written as
- —
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Parent Semax literature, for context
- Reported quantity
- 100–600 µg per day (0.1% intranasal solution)
- Frequency
- Two to three administrations daily
- Study duration
- 3–14 days
A structural analogue does not inherit its parent's pharmacokinetics or its evidence.
Dosage chart
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
Adamax · 10 mg Vial
Adamax is dosed at 300 mcg–1 mg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
- Typical daily range
- 500–1000 µg once daily (gradual titration).
- Easy measuring
- At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 µg on a U‑100 insulin syringe.
- Storage
- Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 1–2 weeks; avoid freeze–thaw cycles.
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 300 µg (0.3 mg) | 9 units (0.09 mL) |
| Weeks 3–4 | 500 µg (0.5 mg) | 15 units (0.15 mL) |
| Weeks 5–6 | 750 µg (0.75 mg) | 23 units (0.23 mL) |
| Weeks 7–8 | 1000 µg (1.0 mg) | 30 units (0.30 mL) |
Reconstitution maths
Vials are typically small (2–10 mg). Without published pharmacokinetics, no meaningful concentration guidance exists.
Open the reconstitution calculatorHow to read these figures
- A compound with no indexed literature cannot have a literature-reported range — that is the honest answer here.
- Identity verification matters more than usual: with no reference pharmacology, mass spectrometry is the only check.
- Claims of greater potency than Semax are commercial, not measured in published work.
Sources and citations
No peer-reviewed primary literature reporting administered quantities exists for this item. Anything circulating online about quantities is anecdote rather than evidence, and this page will not reproduce it. The database links below are kept so you can check for yourself as new work is published.
Search the databases yourself
Read the Adamax research briefOther immune compounds
KPVα-MSH C-terminal tripeptideLL-3737-amino-acid cathelicidin antimicrobial peptideThymalinThymic peptide extract preparationThymosin Alpha-128-amino-acid thymic peptide
All research protocolsPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.